Watching Alzamend Neuro, Inc.? See every signal: funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planAlzamend Neuro, Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
Dr. Lynne Fahey McGrath, a board director since Alzamend Neuro's June 2021 IPO, passed away on July 20, 2026. This represents a loss of experienced biopharmaceutical sector expertise and strategic guidance for the emerging growth company.
Key Takeaways
Dr. Lynne Fahey McGrath, who served as a director since the company's IPO in June 2021, passed away on July 20, 2026
Chairman William B. Horne emphasized Dr. McGrath's significant contributions to the company's strategy and governance
2 more takeaways
Filing Overview
What This Means
Alzamend Neuro, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.